Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer

被引：4

作者：

Soares, Adriana ^{[1
]}

Carmo, Rafael ^{[2
]}

Rodrigues, Catarina ^{[3
]}

Grilo, Ines Teles ^{[4
]}

Grande, Enrique ^{[5
]}

机构：

[1] Unidade Local Saude Matosinhos, Med Oncol Dept, Matosinhos, Portugal

[2] Grp Sasse Oncol & Hematol SOnHe, Med Oncol Dept, Campinas, SP, Brazil

[3] Ctr Hosp Entre Douro & Vouga, Med Oncol Dept, Santa Maria Feira, Portugal

[4] Ctr Hosp Tras Os Montes & Alto Douro, Med Oncol Dept, Vila Real, Portugal

[5] MD Anderson Canc Ctr Madrid, Med Oncol Dept, Madrid, Spain

来源：

BLADDER CANCER | 2020年 / 6卷 / 01期

关键词：

Metastatic bladder cancer; immunotherapy; chemotherapy; CISPLATIN-INELIGIBLE PATIENTS; UROTHELIAL CARCINOMA; URINARY-TRACT; SINGLE-ARM; METHOTREXATE; VINBLASTINE; DOXORUBICIN; MULTICENTER; COMBINATION; GEMCITABINE;

D O I：

10.3233/BLC-190260

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Urothelial tumors are one of the most prevalent cancers worldwide. Cisplatin-based chemotherapy has been the standard first-line treatment for metastatic urothelial cancer (mUC). After nearly three decades of limited advances in the treatment, immune checkpoint inhibitors (ICI) are now available. Responses to immunotherapy (TO) may be long lasting and sustained but only occur in 20-30% of patients. Studies have shown that combining IO with different targeted therapies can lead to potentiating effects with promising results. The first result combining ICI plus chemotherapy shows positive outcomes over standard-of-care in first line mUC. The aim of this article is to review the results, the benefits and new challenges that the combination of chemotherapy and IO can bring to patients with metastatic urothelial carcinoma.

引用

页码：1 / 8

页数：8

共 28 条

[1] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends [J].

Antoni, Sebastien ;

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Znaor, Ariana ;

Jemal, Ahmedin ;

Bray, Freddie .

EUROPEAN UROLOGY, 2017, 71 (01) :96-108

[2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) [J].

Bamias, A. ;

Tzannis, K. ;

Harshman, L. C. ;

Crabb, S. J. ;

Wong, Y. -N. ;

Pal, S. Kumar ;

De Giorgi, U. ;

Ladoire, S. ;

Agarwal, N. ;

Yu, E. Y. ;

Niegisch, G. ;

Necchi, A. ;

Sternberg, C. N. ;

Srinivas, S. ;

Alva, A. ;

Vaishampayan, U. ;

Cerbone, L. ;

Liontos, M. ;

Rosenberg, J. ;

Powles, T. ;

Bellmunt, J. ;

Galsky, M. D. .

ANNALS OF ONCOLOGY, 2018, 29 (02) :361-369

[5] An update on immunotherapy options for urothelial cancer [J].

Bilgin, Burak ;

Sendur, Mehmet A. N. ;

Hizal, Mutlu ;

Yalcin, Bulent .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (12) :1265-1274

[6]

Burtness B., 2019, LANCET LONDON ENGLAN, P1

[7] International Variations in Bladder Cancer Incidence and Mortality [J].

Chavan, Saurabh ;

Bray, Freddie ;

Lortet-Tieulent, Joannie ;

Goodman, Michael ;

Jemal, Ahmedin .

EUROPEAN UROLOGY, 2014, 66 (01) :59-73

[8]

De Santis M., 2019, EORTC STUDY, V30, p[30986, 191]

[9] Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis [J].

Ding, Xiangli ;

Chen, Qiaochao ;

Yang, Zhao ;

Li, Jun ;

Zhan, Hui ;

Lu, Nihong ;

Chen, Min ;

Yang, Yanlong ;

Wang, Jiansong ;

Yang, Delin .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :4171-4184

[10] The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies [J].

Emens, Leisha A. ;

Middleton, Gary .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) :436-443

← 1 2 3 →